BRCA Risk
Calculator

A BRCA risk calculator may estimate either the probability of carrying a harmful BRCA1 or BRCA2 variant or the chance of developing breast or ovarian cancer over a defined period. Those are related—but different—outputs.

Mutation-probability models include BRCAPRO, Penn II, and Myriad. Cancer-risk models include Gail/BCRAT, Tyrer–Cuzick/IBIS, and BOADICEA/CanRisk. Some report 5-year risk; others report 10-year or lifetime risk. Most are more informative when complete history and genetic results are available, yet a calculator cannot provide the genetic data it needs. For foundational context, read the BRCA1 and BRCA2 overview.

Models combine selected factors—age, family cancer history, ancestry or race/ethnicity, breast biopsy history, reproductive history, breast density, lifestyle factors, and sometimes genetic results or polygenic scores—to estimate risk over a stated time horizon.

Each model was trained and validated in particular populations. Inputs that are important in one model may be absent from another. Accurate ages at diagnosis and information from both sides of the family can materially change an estimate; missing history can create false reassurance or unnecessary alarm.

1. 01

   Collect

   Personal, reproductive, biopsy, ancestry, and family-history inputs.

2. 02

   Model

   Apply associations and baseline rates from the model’s development population.

3. 03

   Estimate

   Return a carrier probability or an absolute 5-year, 10-year, or lifetime risk.

4. 04

   Interpret

   Compare the result with clinical thresholds in the context of model fit and data quality.

No single model is best for every person or question. Gail/BCRAT supports general-population breast-risk assessment; Tyrer–Cuzick incorporates broader family and breast factors; BRCAPRO estimates BRCA carrier probability; BOADICEA combines cancer and carrier risk with broader genetics.

AUC summarizes how often a model ranks a case above a non-case; it does not show whether a percentage is well calibrated for an individual. Reported values vary by study and cohort. ^[4,6,8,9]

A calculated lifetime breast cancer risk of about 20% or higher commonly supports discussion of enhanced screening such as annual breast MRI. A BRCA carrier probability around 10% has historically prompted genetics referral, but modern guidelines also use history-based criteria rather than one universal cutoff.

In large cohorts, BRCA1 carriers have had roughly 60–72% lifetime breast cancer risk and 39–58% ovarian cancer risk; BRCA2 estimates are roughly 45–69% and 13–29%, respectively. These are population ranges, not personal forecasts. Polygenic background can move risk within a carrier group; one analysis estimated materially different breast-cancer risk by age 50 across PRS percentiles. ^[3,5,7]

Many established tools predate broad multigene testing. They may not account for PALB2, CHEK2, ATM, RAD51C, RAD51D, BARD1, or the many common variants that contribute to a polygenic risk score.

A targeted familial-variant test asks a precise question and may be the most appropriate first step when a relative's pathogenic variant is known. A hereditary cancer panel analyzes a selected set of genes. Whole-genome sequencing captures a broader data foundation—including coding and non-coding regions—but detection still depends on coverage, validated methods, variant type, and what the service analyzes and reports.

Risk calculators are screening tools, not diagnoses. Performance varies across ages, race and ethnicity groups, and clinical settings. No model can tell whether you will develop cancer, and incomplete family history can make any result unreliable.

• Population fit

  Many models were developed largely in people of European ancestry. Validation and calibration remain uneven for Black, Hispanic, Asian, Indigenous, transgender, and gender-diverse populations.

• Input quality

  Unknown relatives, small families, adoption, early deaths, and inaccurate ages at diagnosis can distort pedigree-based scores.

• Model scope

  BCRAT explicitly does not apply to known BRCA1/2 carriers. Other models vary in the genes, breast-density measures, and lifestyle factors accepted.

• Absolute vs. relative risk

  A large relative increase can still represent a small absolute risk, while a modest relative increase can matter when baseline risk is high.

• Genetic limits

  A negative result may be uninformative if no familial variant is known or the assay did not cover the relevant cause. A VUS is not a positive result.

If your history or a validated score suggests elevated risk, bring the result and a three-generation family history to a healthcare professional or genetic counselor. The next step may be targeted testing, a multigene panel, broader sequencing, or screening based on history alone.

1. 01

   Document the pattern

   Record cancer types, ages at diagnosis, pathology when known, ancestry, and results from both sides of the family.

2. 02

   Choose the right test

   A known familial variant often favors targeted testing. An unexplained pattern may support a hereditary cancer panel or broader approach.

3. 03

   Interpret before acting

   Positive findings may need clinical confirmation. A genetics professional can distinguish a true negative, uninformative negative, and VUS.

4. 04

   Build a care plan

   For appropriate high-risk patients, clinicians may discuss MRI plus mammography, risk-reducing medication, or surgery. These are individualized decisions—not calculator outputs.

Learn who should consider BRCA testing, understand what genetic test results mean, or review the scope of HLI's 30× whole-genome sequencing. The USPSTF gives a Grade B recommendation for risk assessment followed, when indicated, by genetic counseling and testing in women with relevant history or ancestry. ^[1,2,10]